share_log

翰森製藥:自願公告 -「HS-10509片」獲臨床試驗通知書

HANSOH PHARMA: VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL NOTICE OF "HS-10509 TABLETS"

香港交易所 ·  Jan 17 03:30
Summary by Moomoo AI
翰森制药集团有限公司宣布,其自主研发的1类新药「HS-10509片」已获得中国国家药品监督管理局核准签发的临床试验通知书。该药物拟用于治疗精神分裂症,具体适应症将待临床试验后确定。此消息由翰森制药集团有限公司董事会于2024年1月17日发布,董事会成员包括主席兼执行董事钟慧娟女士、执行董事吕爱锋先生及孙远女士;及独立非执行董事林国强先生、陈尚伟先生及杨东涛女士。
翰森制药集团有限公司宣布,其自主研发的1类新药「HS-10509片」已获得中国国家药品监督管理局核准签发的临床试验通知书。该药物拟用于治疗精神分裂症,具体适应症将待临床试验后确定。此消息由翰森制药集团有限公司董事会于2024年1月17日发布,董事会成员包括主席兼执行董事钟慧娟女士、执行董事吕爱锋先生及孙远女士;及独立非执行董事林国强先生、陈尚伟先生及杨东涛女士。
HANSEN PHARMACEUTICAL GROUP CO., LTD. ANNOUNCED THAT ITS INDEPENDENTLY DEVELOPED NEW TYPE 1 DRUG “HS-10509 TABLETS” HAS RECEIVED THE NOTICE OF CLINICAL TRIAL APPROVED BY CHINA'S NATIONAL DRUG ADMINISTRATION. This medicinal product is used to treat schizophrenia. Specific indications will be determined after clinical trials. This announcement was issued by the Board of Directors of Hanssen Pharmaceutical Group Limited on 17 January 2024. The members of the Board include Chairman and Executive Director Ms. Chung Wai-juan, Executive Directors Mr. Lu Aifeng and Ms. Sun Yuan; and Independent Non-Executive Directors Mr. Lin Qiangguo, Mr. Chen Shangwei and Ms. Yang Dongtao.
HANSEN PHARMACEUTICAL GROUP CO., LTD. ANNOUNCED THAT ITS INDEPENDENTLY DEVELOPED NEW TYPE 1 DRUG “HS-10509 TABLETS” HAS RECEIVED THE NOTICE OF CLINICAL TRIAL APPROVED BY CHINA'S NATIONAL DRUG ADMINISTRATION. This medicinal product is used to treat schizophrenia. Specific indications will be determined after clinical trials. This announcement was issued by the Board of Directors of Hanssen Pharmaceutical Group Limited on 17 January 2024. The members of the Board include Chairman and Executive Director Ms. Chung Wai-juan, Executive Directors Mr. Lu Aifeng and Ms. Sun Yuan; and Independent Non-Executive Directors Mr. Lin Qiangguo, Mr. Chen Shangwei and Ms. Yang Dongtao.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more